Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

National Medical Societies Offer Tips To Prevent Injuries; Children Often Victims
- Using a lawn mower can be as routine as bike riding or barbeques during spring and summer months. But often, people find themselves in terrifying situations with these seemingly safe household machines. In fact, 200,000 people - 16,000 of them children - are injured in lawn mower-related accidents each year, the U.S. Consumer Product Safety Commission reports. However, lawn mowers don"t "attack" on their own. Most injuries - such as severed fingers and toes, limb amputations, broken bones, burns and eye injuries - are caused by careless use and can be prevented by following a few simple safety tips.
generic viagra online
AMA Opposes Public Insurance Plan, As Obama Prepares Reform Pitch
America"s largest, most influential physician group said "it will oppose creation of a government-sponsored insurance plan, which President Obama and many other Democrats see as an essential element of legislation to remake the health care system," the New York Times reports. In comments to the Senate Finance Committee, the American Medical Association said, "The introduction of a new public plan threatens to restrict patient choice by driving out private insurers, which currently provide coverage for nearly 70 percent of Americans," and would lead to an "explosion of costs" (Pear, 6/10).
News of the day
Joint Replacement Patients With Diabetes Greatly Benefit From Controlled Glucose
Diabetics undergoing total joint replacement often are at a higher risk of experiencing complications after surgery due to various pre-existing health conditions. According to a new study published in the July 2009 issue of The Journal of Bone and Joint Surgery (JBJS), those complications are less likely to occur when a diabetic patient has glucose levels under control.
Nutrition

Analysis Of Drug-Eluting Stents Data Demonstrates Safety, Efficacy In On-And-Off-Label Use

The Cardiovascular Research Foundation (CRF) announced that results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) were published online June 15 in the journal Circulation. The study also compared the rates of myocardial infarction (MI) and target vessel revascularization (TVR). The analysis - which includes approximately 190,000 patients from 56 studies - was performed by a team of researchers led by Ajay J. Kirtane, MD, Assistant Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons; and an interventional cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center; and Gregg W. Stone, MD, Immediate Past Chairman of the Cardiovascular Research Foundation; Professor of Medicine at Columbia University College of Physicians and Surgeons; and Director of Cardiovascular Research and Education in the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Drs. Kirtane and Stone conducted two parallel meta-analyses examining DES vs. BMS use in both randomized, controlled trials and in observational registry analyses. The overall analysis represents the largest systematic overview of "real-world" (comprising both on-label and off-label) DES use to date and incorporates an overview of both the published literature as well as several unpublished studies presented at major cardiovascular meetings. "The findings from these parallel studies are striking," said Dr. Stone. The meta-analysis of 22 randomized trials included more than 9,000 patients with recent follow-up from previously published trials. According to the results, "DES resulted in no overall differences in death and MI, with a greater than 50% decrease in subsequent target vessel revascularization procedures," said Dr. Stone, adding that these findings are consistent with both on-label and off-label use of DES. And in the 34-study observational meta-analysis (involving more than 180,000 "real-world" patients), "DES resulted in significant 22% and 13% reductions in death and MI, respectively, with a similar reduction in TVR (46%) as in the randomized trials, even after adjustment for confounding variables," said Dr. Stone. "These data are reassuring that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year." The findings were consistent and robust across a variety of study designs; trials that were included were required to follow patients for at least one year. Dr. Kirtane remarked that these findings should help to reassure patients and physicians about the safety of DES in off-label use. "One of the interesting aspects of this analysis is that it points to significant differences between results obtained from randomized trials and observational analyses. Nonetheless, even with the stated limitations of observational data, the bottom line from both randomized trials and observational analyses is consistent: we can reduce the need for repeat procedures and we do not appear to be harming patients with DES," he added. Judy Romero Cardiovascular Research Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009